$23.72
Veracyte is a diagnostics & research business based in the US. Veracyte shares (VCYT) are listed on the NASDAQ and all prices are listed in US Dollars. Veracyte employs 815 staff and has a trailing 12-month revenue of around $375.5 million.
Our top picks for where to buy Veracyte stock
How to buy Veracyte stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – VCYT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Veracyte stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Veracyte stock price (NASDAQ: VCYT)
Use our graph to track the performance of VCYT stocks over time.Veracyte shares at a glance
Latest market close | $23.76 |
---|---|
52-week range | $18.61 - $29.40 |
50-day moving average | $21.97 |
200-day moving average | $23.26 |
Wall St. target price | $30.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.93 |
Is it a good time to buy Veracyte stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Veracyte price performance over time
Historical closes compared with the close of $23.76 from 2024-07-25
1 week (2024-07-19) | 2.50% |
---|---|
1 month (2024-06-27) | 8.05% |
3 months (2024-04-26) | 23.05% |
6 months (2024-01-26) | -9.59% |
1 year (2023-07-27) | -12.78% |
---|---|
2 years (2022-07-27) | -9.38% |
3 years (2021-07-27) | 37.2 |
5 years (2019-07-26) | 29.11 |
Is Veracyte stock undervalued or overvalued?
Valuing Veracyte stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Veracyte's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Veracyte's EBITDA
Veracyte's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $19.7 million.
The EBITDA is a measure of a Veracyte's overall financial performance and is widely used to measure a its profitability.
Veracyte financials
Revenue TTM | $375.5 million |
---|---|
Operating margin TTM | 2.04% |
Gross profit TTM | $195 million |
Return on assets TTM | -0.34% |
Return on equity TTM | -6.2% |
Profit margin | -18.16% |
Book value | $14.64 |
Market Capitalization | $1.8 billion |
TTM: trailing 12 months
Veracyte share dividends
We're not expecting Veracyte to pay a dividend over the next 12 months.
Veracyte share price volatility
Over the last 12 months, Veracyte's shares have ranged in value from as little as $18.61 up to $29.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veracyte's is 1.644. This would suggest that Veracyte's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Veracyte overview
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008.
Frequently asked questions
What percentage of Veracyte is owned by insiders or institutions?Currently 0.823% of Veracyte shares are held by insiders and 105.408% by institutions. How many people work for Veracyte?
Latest data suggests 815 work at Veracyte. When does the fiscal year end for Veracyte?
Veracyte's fiscal year ends in December. Where is Veracyte based?
Veracyte's address is: 6000 Shoreline Court, South San Francisco, CA, United States, 94080 What is Veracyte's ISIN number?
Veracyte's international securities identification number is: US92337F1075 What is Veracyte's CUSIP number?
Veracyte's Committee on Uniform Securities Identification Procedures number is: 92337F107
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
How to buy the new spot Ethereum ETFs
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 top semiconductor stocks to buy in 2024
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
-
11 best brokerage accounts of July 2024: Top picks for investors
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
Ask a question